The hyper-CVAD regimen improves outcome in relapsed acute lymphoblastic leukemia

Leukemia
Charles KollerM Keating

Abstract

Sixty-six adults with refractory acute lymphocytic leukemia received salvage therapy with the 'hyper-CVAD' regimen, consisting of eight courses of alternating intensive chemotherapy with growth factor support, followed by oral maintenance chemotherapy. Their outcome was compared with 63 prognostically similar historical control patients treated with high-dose Ara-C plus mitoxantrone with or without GM-CSF. Overall, the complete response rates were similar in the treatment and control groups (29 of 66 (44%) vs 24 of 63 (38%)). There were more patients in the current study with primary resistant disease (10 of 66 (15%) vs one of 63 (2%), P = 0.006), and conversely fewer patients with secondary resistance (19 of 66 (29%) vs 28 of 63 (44%), P = 0.06). Recovery of granulocyte counts above 500/microl was significantly faster in the current study when compared to high-dose Ara-C-treated patients who were given GM-CSF (20 vs 25 days, P = 0.04). Survival was prolonged in the hyper-CVAD-treated patients, with most of the benefit seen in first salvage patients (42 vs 20 weeks, P = 0.016). When only first salvage patients were considered, there was a significant difference in disease-free survival in favor of hyper-CVAD (52 vs 20 weeks, P ...Continue Reading

Citations

Dec 20, 2003·Blood Reviews·Mark R Litzow
Dec 3, 1999·British Journal of Haematology·F RavandiH M Kantarjian
Apr 12, 2012·Blood·Nicola GökbugetUNKNOWN German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia
Oct 12, 2007·Drugs·Effrosyni ApostolidouFrancis J Giles
Mar 23, 1999·British Journal of Haematology·L P Koh, L C Lim
Dec 3, 2005·Leukemia & Lymphoma·Andrew Grigg
Nov 21, 2013·Leukemia & Lymphoma·Shira DinnerMichaela Liedtke
Mar 16, 2007·Expert Opinion on Emerging Drugs·Yesid AlvaradoFrancis J Giles
Nov 17, 2006·Expert Opinion on Investigational Drugs·Farhad Ravandi, Varsha Gandhi
Nov 19, 2011·Hematology/oncology Clinics of North America·Adele K Fielding
Mar 1, 2011·Critical Reviews in Oncology/hematology·Sujata Narayanan, Paul J Shami
Mar 5, 2016·Current Hematologic Malignancy Reports·Victor D FedorovAmir T Fathi
Nov 22, 2005·Mayo Clinic Proceedings·Elias J JabbourHagop M Kantarjian
Sep 26, 2003·Cancer·Stefan FaderlHagop M Kantarjian
Oct 1, 2011·European Journal of Haematology·Hiroaki ShimizuYoshihisa Nojima
Aug 10, 2013·European Journal of Haematology·Patrice ChevallierFrancoise Kraeber-Bodéré
Jun 9, 2004·Critical Reviews in Oncology/hematology·Renato BassanRoel Willemze
May 29, 2007·Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics·Darren P CoxRichard C K Jordan
Mar 20, 2001·Hematology/oncology Clinics of North America·G Garcia-Manero, D A Thomas
Mar 20, 2001·Hematology/oncology Clinics of North America·T G Martin, J L Gajewski
Dec 18, 2012·Blood·Stephen J Forman, Jacob M Rowe
Sep 8, 2016·Clinical Lymphoma, Myeloma & Leukemia·José Carlos Jaime-PérezDavid Gómez-Almaguer
Nov 7, 2016·Mayo Clinic Proceedings·Shilpa PaulElias J Jabbour

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.